Cisplatin and Epirubicin for Lung Cancer
Author Information
Author(s): Huisman C, Biesma B, Postmus P E, Giaccone G, Schramel F M N H, Smit E F
Primary Institution: Department of Pulmonary Diseases, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
Hypothesis
Is it feasible to administer high-dose epirubicin combined with cisplatin in patients with metastatic non-small-cell lung cancer?
Conclusion
The study found that the combination of accelerated cisplatin and high-dose epirubicin with G-CSF support is feasible and shows promise for treating relapsed non-small-cell lung cancer.
Supporting Evidence
- A total of 27 patients were treated on dose level 4, which appeared to be feasible.
- In the initial study, a total of 86 courses were administered without dose-limiting toxicity.
- 9 partial responses were recorded in 27 patients, indicating a 33% response rate.
Takeaway
Doctors tested a new way to give medicine to lung cancer patients, and it worked pretty well for some of them.
Methodology
Patients received high-dose epirubicin and cisplatin every 2 weeks with G-CSF support, and the regimen's feasibility and efficacy were tested in a phase II study.
Limitations
Myelosuppression limits the use of this regimen to a selected group of patients with good performance status.
Participant Demographics
Patients with relapsed non-small-cell lung cancer, 55% had prior cisplatin-containing chemotherapy.
Statistical Information
Confidence Interval
15%-51%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website